Zilebesiran Therapeutic Hypothesis

Target:
Angiotensinogen (AGT)[1]
siRNA delivery technology:
GalNAc conjugation[1]



Zilebesiran targets *AGT* mRNA in the liver, reducing the production of AGT[1,7,8]

Figure adapted from Cruz-López et al. 2022[3] and Touyz 2023.[8] ACE, angiotensin-converting enzyme; AGT, angiotensinogen; Ang, angiotensin; GalNAc, N-acetylgalactosamine; mRNA, messenger RNA; RAAS, renin–angiotensin-aldosterone system; RNA, ribonucleic acid; siRNA, small interfering RNA.

1. Desai AS et al. N Engl J Med. 2023;389(3):228–38. 2. Benigni A et al. EMBO Mol Med. 2010;2(7):247–57. 3. Cruz-López EO et al. Hypertension. 2022;79(10):2115–26. 4. Morgan ES et al. JACC Basic Transl Sci. 2021;6(6):485–96. 5. Iwanami J et al. Hypertens Res. 2009;32(4):229–37. 6. Ibrahim MM. J Hum Hypertens. 2006;20(2):101–8. 7. Bakris GL et al. JAMA. 2024;331(9):740–9. 8. Touyz RM. N Engl J Med. 2023;389(3):278–81.

Alnylam